If you are wondering whether Vertex Pharmaceuticals' current share price gives you a fair entry point, this article will walk you through what the numbers say about its value. The stock last closed at ...

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a long ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area, too, and ...

Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex ...

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.

Vertex Pharmaceuticals showed strong Q2 2023 earnings, with a 14% revenue increase driven by international sales of Trikafta/Kaftrio and U.S. growth. Management outlined growth initiatives in various ...

Vertex has secured exclusive options to license Skyhawk Therapeutics’ candidates that modulate RNA splicing. The deal will see Vertex pay Skyhawk $40 million upfront and commit to up to $2.2 billion ...

Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from ...

Vertex, Inc. (NASDAQ:VERX) reported weaker-than-expected sales for the second quarter and cut its FY25 sales guidance below estimates on Wednesday. Vertex reported quarterly earnings of 15 cents per ...